Abstract:E3 ligases, essential components of the ubiquitin-proteasome-mediated protein degradation system, play a critical role in cellular regulation. By covalently attaching ubiquitin (Ub) molecules to target proteins, these ligases mark them for degradation, influencing various bioprocesses. With over 600 E3 ligases identified, there is a growing realization of their potential as therapeutic candidates for addressing proteinopathies in cancer and neurodegenerative disorders (NDDs). Recent research has highlighted the need to delve deeper into the intricate roles of E3 ligases as nexus points in the pathogenesis of both cancer and NDDs. Their dysregulation is emerging as a common thread linking these seemingly disparate diseases, necessitating a comprehensive understanding of their molecular intricacies. Herein, we have discussed (i) the fundamental mechanisms through which different types of E3 ligases actively participate in selective protein degradation in cancer and NDDs, followed by an examination of common E3 ligases playing pivotal roles in both situations, emphasising common players. Moving to, (ii) the functional domains and motifs of E3 ligases involved in ubiquitination, we have explored their interactions with specific substrates in NDDs and cancer. Additionally, (iii) we have explored techniques like PROTAC, molecular glues, and other state-of-the-art methods for hijacking neurotoxic and oncoproteins. Lastly, (iv) we have provided insights into ongoing clinical trials, offering a glimpse into the evolving landscape of E3-based therapeutics for cancer and NDDs. Unravelling the intricate network of E3 ligase-mediated regulation holds the key to unlocking targeted therapies that address the specific molecular signatures of individual patients, heralding a new era in personalized medicines.

Interlinked destinies: How ubiquitin-proteasome and autophagy systems underpin neurocognitive outcomes

UBE3A: Bridging the gap between neurodevelopment, neural function, and neurodegenerative woes

Understanding ubiquitination in neurodevelopment by integrating insights across space and time

Neuronal UBE3A substrates hold therapeutic potential for Angelman syndrome

Crosstalk between ubiquitination and translation in neurodevelopmental disorders

Deubiquitylating enzymes in neuronal health and disease

ER stress and the unfolded protein response in neurodegeneration

Ubiquitin E3 ligases assisted technologies in protein degradation: Sharing Pathways in Neurodegenerative Disorders and Cancer

Deubiquitinating enzymes (DUBs): decipher underlying basis of neurodegenerative diseases

Multiscale spatio-temporal dynamics of UBE3A gene in brain physiology and neurodevelopmental disorders

The Autophagy–Lysosomal Pathway in Neurodegeneration: A TFEB Perspective

Enhancement of Lysosome Biogenesis As a Potential Therapeutic Approach for Neurodegenerative Diseases.

The Molecular Mechanisms of Ubiquitin-Proteasome System Effecting on Cognition

The Proteasome-Associated Deubiquitinating Enzyme Usp14 Is Essential For The Maintenance Of Synaptic Ubiquitin Levels And The Development Of Neuromuscular Junctions

E3 ligase recruitment by UBQLN2 protects substrates from proteasomal degradation

UBE3A reinstatement as a disease‐modifying therapy for Angelman syndrome

An atypical ubiquitin ligase at the heart of neural development and programmed axon degeneration

Mechanism and Disease Association with a Ubiquitin Conjugating E2 Enzyme: UBE2L3

Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases

Integrated Proteomics Reveals the Landscape of Autophagy Degradation in Human Neurons and Autophagy Receptors Regulating Neuronal Activity

A Survey on the Expression of the Ubiquitin Proteasome System Components HECT- and RBR-E3 Ubiquitin Ligases and E2 Ubiquitin-Conjugating and E1 Ubiquitin-Activating Enzymes during Human Brain Development